Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at rutlandherald.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

Twist Bioscience has partnered with Lilly TuneLab to provide high-quality antibody characterization data that supports AI/ML drug discovery models, aiming to accelerate antibody drug development through integrated experimental and AI-driven approaches.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You now have access to AI models trained on top-tier antibody data from Twist, creating a shortcut to better candidate selection and faster drug discovery cycles. This opens a door to move beyond slow lab processes by integrating predictive AI insights.

◆ Coverage

2 sources · 16 Sep 2026

◆ Related on Wire

◆ Topics

Biotechantibody-discoveryai-mldrug-developmentbiotech-collaborationwet-lab-data